Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

NCT07738172 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasms, Non-Small Cell Lung Cancer

Interventions

PROCEDURE: Primary Tumor Resection
DRUG: Osimertinib

Sponsor

National Taiwan University Hospital